RAMIPRIL capsule

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

RAMIPRIL (UNII: L35JN3I7SJ) (RAMIPRILAT - UNII:6N5U4QFC3G)

Pieejams no:

DIRECT RX

SNN (starptautisko nepatentēto nosaukumu):

RAMIPRIL

Kompozīcija:

RAMIPRIL 5 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

1.1 Hypertension Ramipril capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classe

Produktu pārskats:

Ramipril Capsules USP are available in 1.25 mg, 2.5 mg, 5 mg, and 10 mg hard gelatin capsules. Descriptions of Ramipril Capsules USP are summarized below. Ramipril Capsules USP, 1.25 mg are: Size "4" capsules with yellow cap, imprinted with 'LUPIN' in black ink and yellow body imprinted with 'RAMIPRIL 1.25 mg' in black ink, containing white to off-white powder. NDC 68180-588-09    bottles of 90 NDC 68180-588-01    bottles of 100 NDC 68180-588-02    bottles of 500 Ramipril Capsules USP, 2.5 mg are: Size "4" capsules with orange cap, imprinted with 'LUPIN' in black ink and orange body imprinted with 'RAMIPRIL 2.5 mg' in black ink, containing white to off-white powder. NDC 68180-589-09    bottles of 90 NDC 68180-589-01    bottles of 100 NDC 68180-589-02    bottles of 500 Ramipril Capsules USP, 5 mg are: Size "4" capsules with red cap, imprinted with 'LUPIN' in black ink and red body imprinted with 'RAMIPRIL 5 mg' in black ink, containing white to off-white powder. NDC 68180-590-09    bottles of 90 NDC 68180-590-01    bottles of 100 NDC 68180-590-02    bottles of 500 Ramipril Capsules USP, 10 mg are: Size "4" capsules with light blue cap, imprinted with 'LUPIN' in black ink and light blue body imprinted with 'RAMIPRIL 10 mg' in black ink, containing white to off-white powder. NDC 68180-591-09    bottles of 90 NDC 68180-591-01    bottles of 100 NDC 68180-591-02    bottles of 500 Dispense in light-resistant, tight container with child-resistant closure.  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

RAMIPRIL- RAMIPRIL CAPSULE
DIRECT RX
----------
RAMIPRIL
BOXED WARNING SECTION
When pregnancy is detected, discontinue ramipril as soon as possible (
5.6).
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the
developing fetus ( 5.6).
INDICATIONS & USAGE SECTION
1.1 Hypertension
Ramipril capsules USP are indicated for the treatment of hypertension,
to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal
cardiovascular events, primarily strokes
and myocardial infarctions. These benefits have been seen in
controlled trials of antihypertensive drugs
from a wide variety of pharmacologic classes including this drug.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking cessation,
exercise, and limited sodium intake. Many patients will require more
than one drug to achieve blood
pressure goals. For specific advice on goals and management, see
published guidelines, such as those
of the National High Blood Pressure Education Program's Joint National
Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different
mechanisms of action, have been shown in randomized controlled trials
to reduce cardiovascular
morbidity and mortality, and it can be concluded that it is blood
pressure reduction, and not some other
pharmacologic property of the drugs, that is largely responsible for
those benefits. The largest and
most consistent cardiovascular outcome benefit has been a reduction in
the risk of stroke, but reductions
in myocardial infarction and cardiovascular mortality also have been
seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk
increase per mmHg is greater at higher blood pressures, so that even
modest reductions of severe
hypertension ca